CorMedix (CRMD) Q2 2026 Earnings Call Transcript

CorMedix reported Q2 2026 revenue of $101.9M (vs. $39.7M y/y) and adjusted EBITDA of $58.7M (vs. $22.4M), driven by DefenCath utilization and a full-quarter contribution from the Melinta portfolio. The company reiterated full-year 2026 revenue guidance of $325M–$345M but raised adjusted EBITDA guidance to $125M–$140M (from a prior range), citing improved performance and visibility post-TDAPA. Commercial momentum also improved after signing a new multi-year supply agreement with a large dialysis organization (initial pilot “a couple hundred clinics” in Q3 2026) and the Phase III ReSPECT study met its day-90 primary endpoint for REZZAYO prophylaxis non-inferiority, with an sNDA submission expected in Q3 2026.

Analysis

The key shift is durability, not the quarter. CorMedix is moving from a reimbursement-sensitive one-product story toward an embedded workflow vendor in dialysis, and that should lower churn risk, reduce customer concentration discount, and support a higher EV/EBITDA multiple if volumes hold through the post-transition noise. The attrition in the smallest accounts is actually constructive for mix: it can improve unit economics and operational focus, while also accelerating consolidation toward large operators that are more likely to sign multi-year deals.

The bigger underappreciated asset is the pipeline optionality. REZZAYO is still a 2027+ event, but once the U.S. asset transfers, CorMedix will control a second, higher-margin commercial lever that the market is not fully embedding into near-term valuation. The risk is label narrowness: if the eventual prophylaxis label is tighter than the Street expects, the asset stays a call option rather than a core driver.

Near term, the stock is still hostage to two catalysts: November ESRD reimbursement details and whether the new large-dialysis pilot expands beyond a modest initial footprint. The current setup is vulnerable to a disappointment if Q4 ordering slows or if the final payment rule worsens economics; that would hit 2027 expectations before Medicare Advantage can offset it. Conversely, sustained LDO expansion plus any early MA wins would likely trigger multiple expansion because investors would gain confidence that the franchise is self-funding before REZZAYO contributes.

Key Decisions for Investors

• Accumulate CRMD on post-earnings weakness for a 3-6 month hold into the November ESRD rule and Q4 real-world evidence readout; thesis is de-risked base business plus underappreciated pipeline optionality. Falsify if sequential DefenCath volumes roll below the current run-rate or the final ESRD rule weakens reimbursement economics.
• For convexity, buy 12-18 month CRMD call exposure via LEAPS or a call spread rather than outright stock if liquidity allows; the goal is to monetize the 1H27 REZZAYO decision window without overpaying for time. The trade works if the market starts capitalizing REZZAYO as an owned U.S. asset instead of a partnered program.
• Set a watch alert on the new LDO pilot: if clinic rollout expands materially beyond the initial couple hundred sites by Q4, add to CRMD. If adoption stalls, take profits into any rally because 2027 growth would then depend almost entirely on Medicare Advantage contracting.
• No aggressive short in dialysis providers here; the more likely second-order effect is a modest shift of volume toward large operators and away from small independents, not a margin shock to DVA/FMS. Use CRMD as the expression, not the downstream customer base.